Valuation: AstraZeneca PLC

Market Cap 272B 1,610B 248B 229B 208B 391B 25,252B 412B 2,786B 1,106B 13,765B 1,022B 1,001B 43,194B P/E 2026 *
23x
P/E 2027 * 19.8x
Enterprise Value 293B 1,733B 267B 246B 224B 421B 27,183B 443B 2,999B 1,191B 14,817B 1,100B 1,077B 46,496B EV / Sales 2026 *
4.63x
EV / Sales 2027 * 4.25x
Free-Float
96.62%
Yield 2026 *
1.9%
Yield 2027 * 2.02%
1 day-1.09%
1 week-0.17%
Current month+3.06%
1 month+23.59%
3 months+22.43%
6 months+10.89%
Current year+3.22%
1 week 170.89
Extreme 170.89
178.99
1 month 133.15
Extreme 133.15
178.99
Current year 129.06
Extreme 129.06
190.4
1 year 129.06
Extreme 129.06
190.4
3 years 101.6
Extreme 101.6
190.4
5 years 93.74
Extreme 93.74
190.4
10 years 93.74
Extreme 93.74
190.4
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%-0.17% - - 272B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+27.26%+67.32% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+27.23%+51.59% 288B
+0.81%-4.08%-1.74%+32.71% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.19%-4.76%+25.66%+75.96% 452B
Weighted average by Cap. +0.21%-5.19%+26.46%+88.08%

Financials

2026 *2027 *
Net sales 63.38B 374B 57.79B 53.21B 48.45B 90.88B 5,873B 95.81B 648B 257B 3,201B 238B 233B 10,046B 67.39B 398B 61.46B 56.58B 51.52B 96.64B 6,245B 102B 689B 274B 3,404B 253B 248B 10,683B
Net income 11.69B 69.07B 10.66B 9.82B 8.94B 16.77B 1,084B 17.68B 120B 47.48B 591B 43.86B 42.94B 1,853B 13.59B 80.29B 12.39B 11.41B 10.39B 19.49B 1,260B 20.55B 139B 55.19B 687B 50.99B 49.92B 2,154B
Net Debt 20.83B 123B 19B 17.49B 15.93B 29.87B 1,931B 31.49B 213B 84.59B 1,052B 78.15B 76.51B 3,302B 13.65B 80.62B 12.45B 11.46B 10.43B 19.57B 1,265B 20.63B 140B 55.42B 689B 51.2B 50.12B 2,163B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
19/11/26 R$174.09 -1.09% 179
18/11/26 R$176.00 +0.56% 90
17/11/26 R$175.02 -1.06% 1,014
16/11/26 R$176.90 +1.45% 348
13/11/26 R$174.38 +0.30% 108
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
175.69USD
Average target price
215.31USD
Spread / Average Target
+22.55%